EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudie

Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study

Hirofumi Miyake iD, Ayana Okazaki, Shogo Matsuda, Yuichi Masuda, Takuya Kotani iD, Muneyuki Hatta, Mayu Shiomi, Ryu Watanabe iD, Motomu Hashimoto iD, Hideki Oka iD, Shuji Sumitomo iD, Kaho Jo und 6 weitere

Modern Rheumatology · 2025

DOI: 10.1093/mr/roaf124 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Modern Rheumatology, 2025. Verfasst von Hirofumi Miyake und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Internal Medicine, Tenri Hospital, Nara, Japan. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Cyclophosphamide, Rituximab, Immunosuppressive Agents. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare the efficacy and safety of rituximab (RTX) to those of intravenous cyclophosphamide (IVCY) as remission induction therapy in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and severe renal impairment.

Methods

Using the REVEAL cohort, this retrospective multicentre study enrolled 96 newly diagnosed patients with AAV and an estimated glomerular filtration rate of < 30 ml/min/1.73 m2. The patients were divided into RTX and IVCY groups. Matching weights were used to adjust for baseline characteristics. The primary outcome was a 2-year composite of all-cause mortality or end-stage kidney disease (ESKD). Secondary outcomes included all-cause mortality, ESKD, relapse, and hospitalisation-requiring infections. Outcomes were assessed using multivariable Cox proportional hazards models.

Results

In the weighted population, the hazard ratio for RTX versus IVCY was 0.73 (95% confidence interval: 0.31–1.72) for the primary composite outcome, with no significant intergroup difference. Similarly, intergroup differences in the hazard ratios for all-cause mortality, ESKD, relapses, and hospitalisation-requiring infections were not significant.

Conclusions

RTX and IVCY demonstrated comparable efficacy in preventing mortality and ESKD in this high-risk population. RTX is a viable option for patients with AAV and severe renal impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisCyclophosphamideRituximabImmunosuppressive AgentsAntirheumatic AgentsHumansFemaleRetrospective StudiesMaleMiddle AgedAgedTreatment OutcomeKidney Failure, ChronicGlomerular Filtration RateAdministration, Intravenous

Stichwörter der Autor:innen

Anti-neutrophil cytoplasmic antibody-associated vasculitisintravenous cyclophosphamiderituximabsevere renal impairment

Substanzen

CyclophosphamideRituximabImmunosuppressive AgentsAntirheumatic Agents

Autor:innen und Institutionen

  • Department of General Internal Medicine, Tenri Hospital, Nara, Japan.
  • Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Department of Rheumatology, Kobe City Medical Center General Hospital, Hyogo, Japan.
  • Division of Clinical Immunology and Rheumatology, Yodogawa Christian Hospital, Osaka, Japan.
  • Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan.

ORCID-Profile: Hirofumi Miyake, Takuya Kotani, Ryu Watanabe, Motomu Hashimoto, Hideki Oka, Shuji Sumitomo, Ryosuke Hiwa

Zitieren

APA

Miyake, H., Okazaki, A., Matsuda, S., Masuda, Y., Kotani, T., Hatta, M., Shiomi, M., Watanabe, R., Hashimoto, M., Oka, H., Sumitomo, S., Jo, K., Fujiki, Y., Yamamoto, W., Taniguchi, T., Shoji, M., Manabe, A., & Hiwa, R. (2025). Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roaf124

Vancouver

Miyake H, Okazaki A, Matsuda S, Masuda Y, Kotani T, Hatta M, et al. Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study. Modern Rheumatology. 2025. doi:10.1093/mr/roaf124

BibTeX
@article{Miyake2025,
  author = {Miyake, Hirofumi and Okazaki, Ayana and Matsuda, Shogo and Masuda, Yuichi and Kotani, Takuya and Hatta, Muneyuki and Shiomi, Mayu and Watanabe, Ryu and Hashimoto, Motomu and Oka, Hideki and Sumitomo, Shuji and Jo, Kaho and Fujiki, Yohei and Yamamoto, Wataru and Taniguchi, Tomoki and Shoji, Mikihito and Manabe, Atsushi and Hiwa, Ryosuke},
  title = {Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study},
  journal = {Modern Rheumatology},
  year = {2025},
  doi = {10.1093/mr/roaf124}
}
Kostenlos starten →